Glenmark's Lead Compound For COPD Fails; Forest To Wait For 2010 Studies In Asthma Patients

MUMBAI - Hopes of a novel drug to treat smoking-induced lung disease were dashed after India's Glenmark Pharma and its U.S.-based research partner Forest Labs announced that the compound under development in Phase IIb human trials failed to meet efficacy endpoints